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Aim: To evaluate the anatomical and visual outcomes as well as the safety of combination therapy with
dexamethasone intravitreal implant (0.7 mg) and bevacizumab in macular edema secondary to vascular
occlusions.
Methods: In this interventional, prospective case series all patients received dexamethasone implant and
bevacizumab in a single sitting. Patients diagnosed with retinal venous occlusion were monitored for
changes in visual acuity and macular thickness. All patients underwent detailed ocular examination, best
corrected visual acuity (BCVA), and optical coherence tomography examination at baseline and at Week
1, Month 1, and monthly thereafter for 6 months.
Results: Twenty four eyes of 24 treatment-naïve patients (central retinal venous occlusion, n ¼ 9; branch
retinal venous occlusion, n ¼ 15) were identiﬁed. BCVA improved in 23 patients (95.83%) during the
study period. Mean BCVA gained was 0.313  0.26 (85.3% of ﬁnal gain) and 0.367  0.34 at Week 1 and
Month 6, respectively. The percentage of patients who gained 2 lines were 52% at Week 1 and 68% at
Month 6. The mean macular thickness reduced by 350.9 mm at Week 1 and the maximum treatment
effect was seen at Month 2 (379.1 mm). Recurrence of macular edema was seen in 37.5% (9/24) of the eyes.
Reinjection was needed, on average, at approximately 3.7 months from the ﬁrst injection.
Conclusion: This study demonstrates that the combination therapy of bevacizumab and dexamethasone
implant given simultaneously is safe and synergistic resulting in signiﬁcantly early and sustained visual
recovery and decreased macular edema in patients having retinal vein occlusions.
Copyright  2014, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Retinal vein occlusion (RVO) is amajor cause of vision loss due to
vascular diseases of the retina. In population-based studies of
middle-aged and older adults, the prevalence of RVO as a whole
ranged from 0.7% to 1.6%, making it the second most common
retinal vascular disorder, following diabetic retinopathy.1,2
Macular edema is among the most prevalent causes of vision
loss in both branch and central retinal venous occlusion (BRVO and
CRVO).3 Even though the pathogenesis of macular edema in RVOs is
not yet fully understood, the presence of inﬂammatory cytokines as
well as vascular permeability factors, such as interleukin-6,y proprietary and ﬁnancial
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ciety of Taiwan. Published by Elseprostaglandins, vascular endothelial growth factors (VEGFs), and
the consecutive breakdown of the blooderetina barrier due to
endothelial cell dysregulation are postulated to cause macular
edema.4e6
Until recently, our treatment strategy for patients with RVO was
mainly based on the results of BRVO and CRVO trials suggesting
deferred focal laser for macular edema in BRVO patients with best
corrected visual acuity (BCVA) below 20/40.7,8 Peripheral laser was
recommended only for severe ischemia in RVO to treat/prevent
anterior or posterior segment neovascularization, especially in
CRVO; however, macular laser photocoagulation had no beneﬁt at
all in improving the macular function in eyes with CRVO. Recent
randomized control trials have independently investigated and
demonstrated the potential beneﬁts of intravitreal therapy with the
corticosteroids triamcinolone acetonide (the Standard Care vs
Corticosteroid for Retinal Vein Occlusion trial),9,10 ranibizumab
(Lucentis; Genentech, Inc., BRAVO/CRUISE studies),11e14 bev-
acizumab (Avastin; Genentech, Inc),15e17 and dexamethasone
intravitreal implant [dexamethasone implant; Allergan, Inc, Irvine,vier Taiwan LLC. All rights reserved.
Table 1
Demographic characteristics of the study population.
Number of patients n ¼ 24
Sex Male 16 (66.67)
Female 08 (33.33)
Type of retinal venous occlusion CRVO 09 (37.5)
BRVO 15 (62.5)
Mean age (y) 54.9  12.5
Study horizon 6 mo
No. of patients requiring reinjection 09 (37.5)
Average time of reinjection 3.7  1.5 mo
Data are presented as n (%) or mean  SD.
BRVO ¼ branch retinal venous occlusion; CRVO ¼ central retinal venous occlusion.
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group]18,19 in RVO. However, the studies show that there were
major concerns about intraocular pressure (IOP) increase in pa-
tients treated with triamcinolone acetonide whereas repeated
treatments with anti-VEGF agents are often required to control
macular edema, prevent visual loss, and increase the chances of
visual improvement.
The action of bevacizumab starts at 24 hours and the action
persists for 3e4 weeks,20,21 whereas with the dexamethasone
implant, the duration of peak action is at 2 months.22 It has been
noted that anti-VEGF and dexamethasone implant have a syner-
gistic action (where dexamethasone implant was injected after 2
weeks of bevacizumab), increasing visual acuity and prolonging the
time between injections, comparedwith either medication alone.23
We carried out this study to determine whether dexamethasone
implant and bevacizumab act synergistically when injected
simultaneously in a single sitting in reducing the macular thickness
and improving the visual acuity as well as to assess the safety
proﬁle of the combination in these patients.
2. Materials and methods
This prospective case series is a nonrandomized, non-
comparative open-label, single-center investigation carried out at a
tertiary eye care center after obtaining approval from the Institu-
tional Review Board/Ethics Committee and informed consent from
all patients.
Treatment-naïve individuals who were at least 18 years of age,
with a BCVA of 20/40 or worse, and macular edema  300 mm on
optical coherence tomography (OCT) secondary to RVO were
recruited. Patients having clinically signiﬁcant media opacity, his-
tory of vitrectomy and/or rubeotic or advanced glaucoma (deﬁned
as cup-to-disk ratio of 0.8 or worse), ocular hypertension (requiring
> 1 medication to control IOP) in the study eye, a history of steroid-
induced IOP increase in either eye, aphakia, currently using or
anticipating the use of systemic steroids or anticoagulants during
the study, with known allergy/hypersensitivity to the study medi-
cation or their components, and previous use of dexamethasone
implant were excluded.
All patients were evaluated at baseline and every subsequent
visit with BCVA, slit-lamp examination, indirect ophthalmoscopic
examination, IOP measurement, and OCT (Spectralis OCT, Heidel-
berg Engineering, Heidelberg, Germany). Each participant received
bevacizumab injection and dexamethasone implant (0.7 mg) at
baseline in a single sitting. Patients were seen on the 7th day, 1st
month, and every month thereafter.
Outcomes were evaluated for visual, anatomical, and safety
parameters. Improvement in BCVA was deﬁned as the ability to
read 2 lines on the Snellen visual acuity chart from baseline.
Anatomical outcomes were evaluated by measuring the central
retinal thickness on Spectralis OCT. By taking a reference scan every
time it was ensured that the follow-up scan was passing through
the same region. Our criteria for retreatment included loss of BCVA
 1 line on the Snellen visual acuity chart and/or an increase in
retinal thickness on OCT > 100 mm. Dexamethasone implant was
used as the drug of reinjection. Safety parameters included
increased risk of IOP increase, endophthalmitis, vitreous hemor-
rhage, or retinal detachment. A relevant increase in IOPwas deﬁned
as an increase >5 mm of Hg compared with the baseline.
The dexamethasone implant was inserted through the pars
plana (inferotemporal quadrant) under topical anesthesia. All en-
tries were created in a biplanar fashion using trocar ﬁxation plate
(pressure plate forceps) from ASICO (Westmont, IL, USA). Initially,
the dexamethasone implant injection is administered at a 30 angleuntil the applicator bevel and then perpendicular to globe up to the
silicone sleeve. At this point, the actuator button was pressed until
an audible click was heard. The implant could be seen ejected out of
the needle tip under direct microscope visualization. The needle
was withdrawn in the same direction and the entry/exit wound
was massaged with a steel-made scleral indenter.
Following the dexamethasone implant, intravitreal bevacizumab
(1.25 mg/0.05 cc) was injected at a different site with a 30-g needle
3.5 mm in pseudophakic and 4 mm in phakic eyes posterior to the
limbus. Povidone-iodine was instilled in the conjunctiva prior to
and after the injection. Following the intravitreal injections, pa-
tients were monitored for signs of inﬂammation, endophthalmitis,
and elevation in IOP. All these patients were treated with a topical
antibiotic four times daily for 5e7 days. For statistical analysis, the
BCVAvalue (Snellen visual acuity chart) was converted into logMAR
and paired t test was applied.
3. Results
Twenty four eyes of 24 patients (n ¼ 24) were analyzed in this
study. The population consisted of 16 males (66.66%) and eight
females (33.33%), with a mean age of 54.75 years. Nine of these
patients were diagnosed with CRVO, whereas another 15 were
diagnosed with BRVO (Table 1).
There was a recurrence of macular edema in 41% (9/24) of eyes,
which satisﬁed the criteria of retreatment prior to Month 6. Ana-
lyses of this subgroup revealed that four were CRVO and ﬁve were
BRVO patients. Reinjection was needed, on average, at approxi-
mately 3.7 months from the ﬁrst injection (Fig. 1). Dexamethasone
implant was used as the drug of reinjection.
The visual acuity results showed that 95.8% (23/24) of patients
gained vision during the 6 months of observation, whereas 4.2%
(1/24) had no change. The overall mean baseline BCVA and at all
follow ups are shown in Table 2. The mean BCVA (logMAR) gained
was 0.313  0.26, 0.362  0.29, 0.401  0.34, 0.388  0.35,
0.376  0.34, 0.375  0.52, and 0.367  0.34 for visits at Week 1,
Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6,
respectively, and the values were statistically signiﬁcant in all
follow ups (Fig. 2). The mean BCVA gain was maximum at Week 1
(85.3% of ﬁnal mean BCVA gain) and themaximum treatment effect
in terms of visual gain was seen at Month 2 (Fig. 2). The percentage
of patients who gained 2 lines compared with baseline were 52%
at Week 1 and 68% at Month 6.
3.1. Subgroup analysis
Improvement in BCVA values was noted in all cases of CRVO
(9/9) and in 14 of 15 cases in BRVO. In the single patient, who did
not show improvement, the duration of disease was 4 months. The
mean BCVA (baseline and in all follow ups) values in CRVO and
BRVO cases are shown in Table 2. The mean BCVA (logMAR) gain in
the CRVO subgroup was 0.426  0.3, 0.447  0.32, 0.531  0.42,
Fig. 1. Distribution of time for reinjection. Fig. 2. Mean best corrected visual acuity (BCVA) improvement over time.
BRVO ¼ branch retinal venous occlusion; CRVO ¼ central retinal venous occlusion.
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BRVO subgroup it was 0.244  0.22, 0.311  0.27, 0.322  0.26,
0.315  0.31, 0.315  0.31, 0.313  0.31, and 0.314  0.31 at Week 1,
Month 1, Month 2, Month 3, Month 4, Month 5, and Month 6,
respectively (Fig. 2). The maximummean BCVA gain of total gain at
6 months was noted at Week 1 (94% in CRVO and 77.7% in BRVO)
and the maximum treatment effect in terms of visual gainwas seen
at Month 2 in both the subgroups (Fig. 2). The percentage of pa-
tients who gained 2 lines compared with baseline were 40% and
66.6% in BRVO cases as compared with 77.8% and 88.9% in CRVO
cases at Week 1 and Month 6, respectively.
The overall mean OCT thickness at baseline and all follow ups
are detailed in Table 2. The overall mean reduction in OCT thickness
(in mm) noted was 350.92  236.3, 367.29  235.2, 379.12  238.2,
334  231.3, 348.54  251.1, 354.17  240.3, and 322.5  228.2 at
Week 1, Month 1, Month 2, Month 3, Month 4, Month 5, and Month
6, respectively (Fig. 3). The maximum OCT thickness reduction was
noted at Week 1, macular thickness improved by 350.9 mm, and the
maximum treatment effect was seen at Month 2 (379.1 mm). The
OCT measurements showed a statistically signiﬁcant reduction in
central retinal thickness at all follow ups (p > 0.05).
3.2. Subgroup analysis
The mean OCT thickness of subgroups CRVO and BRVO at
baseline and all follow ups is shown in Table 2. In both the sub-
groups, the maximum amount of reduction in OCT thickness was
noted at Week 1 and the maximum treatment effect was seen at
Month 2 (Fig. 3).
During the 6-month follow up, 16.6% (4/24) patients experi-
enced an increase in IOP and were controlled with antiglaucoma
topical medications alone. One patient had superﬁcial retinal
hemorrhage that can be due to the direct impact of implant on
retina. No other adverse events such as vitreous hemorrhage,
retinal detachment, or endophthalmitis were noted. No accelerated
cataract formation was noted in phakic eyes.Table 2
Mean BCVA/OCT thickness (baseline and all follow ups) divided by disease types.
Baseline Week 1 Month 1 Month 2
Mean BCVA (in logMAR units)
All points 0.723  0.45 0.410  0.33 0.361  0.31 0.322  0.3
CRVO 0.744  0.59 0.318  0.33 0.298  0.31 0.213  0.2
BRVO 0.709  0.37 0.465  0.33 0.399  0.31 0.387  0.3
Mean central retinal thickness (in mm)
All points 605.1  251.2 254.2  56.8 237.8  44.3 235.0  43
CRVO 754.4  178.9 280.0  69.3 262.5  44.3 264.0  44
BRVO 515.5  249.9 238.7  43.3 223.0  38.4 217.6  34
Data are presented as mean  SD.
BCVA ¼ best corrected visual acuity; BRVO ¼ branch retinal venous occlusion; CRVO ¼ c4. Discussion
Because of increasing awareness of the role of inﬂammatory
mediators in the pathogenesis of macular edema secondary to RVO,
these patients have a better chance of visual recovery with intra-
vitreal application of corticosteroids18,19 and anti-VEGF drugs.11e17
Both pharmacological approaches address important issues in the
pathogenesis of retinal vascular occlusion, such as the expression of
VEGF in the vitreous and inﬂammatory processes.4e6
Anti-VEGF drugs (ranibizumab/bevacizumab) have a beneﬁcial
effect on visual function and reduce central macular thickness in
BRVO and CRVO eyes.11e17 However, with respect to their shorter
half-life, numerous injections are required to achieve and maintain
this therapeutic effect.
Dexamethasone is a potent, water-soluble corticosteroid that
can be delivered into the vitreous cavity either by injection of a
dexamethasone solution with a very short half-life or by the
approved dexamethasone implant using a customized applicator
system. The dexamethasone implant is composed of a biodegrad-
able co-polymer of lactic acid and glycolic acid containing
micronized dexamethasone. The drugeco-polymer complex grad-
ually releases the total dose of dexamethasone over a series of up to
6 months and has a beneﬁcial effect on visual acuity and retinal
thickness in patients with macular edema associated with RVO.18,19
The aim of this study was to determine the combined effect of a
sustained-release corticosteroid injection with an anti-VEGF and
also whether the combination provides early and sustained
improvement in visual acuity and reduction in OCT thickness over a
period of 6 months.
This study shows that the combination of dexamethasone
implant and bevacizumab therapy injected simultaneously is syn-
ergistic in increasing visual acuity, decreasing the retinal thickness,
and lengthening the time between injections as compared with
either medication alone.11e19 In a study carried out by Singer et al23
inwhich RVO patients were injected with bevacizumab at baseline,
followed by dexamethasone intravitreal implant injection 2 weeksMonth 3 Month 4 Month 5 Month 6
0.334  0.27 0.347  0.27 0.348  0.28 0.356  0.3
3 0.233  0.22 0.267  0.23 0.267  0.26 0.291  0.32
2 0.395  0.29 0.395  0.29 0.396  0.29 0.395  0.29
.9 271.1  103.1 256.6  75.2 250.9  57.4 282.6  114.3
.4 274.0  71.7 283.7  95.3 262.1  39.1 295.0  111.8
.2 269.4  120.4 240.3  57.8 244.3  66.5 275.2  119.0
entral retinal venous occlusion; OCT ¼ optical coherence tomography.
Fig. 3. Mean optical coherence tomography retinal thickness improvement over time.
BCVA ¼ best corrected visual acuity; BRVO ¼ branch retinal venous occlusion;
CRVO ¼ central retinal venous occlusion.
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central retinal thickness< 300 mm. This number increased to 68% at
Week 4 (23/34) once the dexamethasone implant was added.
Compared with these results, in our study, at Week 1, 71% (17/24)
had central retinal thickness < 300 mm, which further improved to
83% (20/24) at Month 1. Of note, the mean pretreatment central
retinal thickness in our study was 605 mm as compared with only
513 mm in the aforementioned study, which demonstrates the early
and better beneﬁts of this combination therapy.
The previously mentioned study23 also noted BCVA improve-
ment in 97% of cases, of which 55% of cases had a maximum visual
acuity gain of three lines of the Snellen visual acuity chart and 82%
required reinjection around the average time of 125.9  25.5 days.
Our study showed similar results with BCVA improvement noted in
95.8% patients with 54% having maximum visual acuity gain 3
lines and only 37.5% required reinjection at an average time of 3.7
months. If one compares our results in terms of visual acuity
improvement with other RVO studies with monotherapy, differ-
ences become very apparent. In the GENEVA/dexamethasone
implant studies,18,19 only 29.3% of patients gained three lines of
vision. In the bevacizumab study by Stahl et al,15 all patients
experienced a mean 2.4 line increase in visual acuity when
compared with baseline versus the current study, in which the
mean gain is 2.94 lines. Mayer et al24 found that pretreatment with
three doses of bevacizumab followed by a single dexamethasone
implant was not effective in prolonging the interval until recur-
rence of macular edema as compared with monotherapy using the
dexamethasone implant in the ﬁrst instance. The average recur-
rence time for edema was noted to be approximately 3.55 months,
and increased IOP was noted in 55.1% of the cases.
Looking at the safety proﬁle, the current study had 16.6% (4/24)
of patients with increased IOP and is similar to the GENEVA/
dexamethasone implant study18,19 and Singer et al study23 inwhich
increased IOP was noted in 12.6% and 18% of patients, respectively.
No other adverse events such as vitreous hemorrhage, retinal
detachment, or endophthalmitis were noted.
We performed the study to take advantage of the different
modalities available to treat RVO. The aim of our combination study
was to have early and sustained visual and anatomical recovery by
taking advantage of bevacizumab’s early onset of action and
dexamethasone implant’s gradual release, thereby minimizing the
number of injections during the study period. In our study, 85.3% of
the ﬁnal mean BCVA gain was achieved as early as Week 1 and the
maximum effect was seen at Month 2. In addition, the maximum
mean reduction in retinal thickness noted was 379.1 mm at Month
2, of which 350.9-mm mean reduction was noted by Week 1. The
GENEVA/dexamethasone implant18,19 data show maximum effect
in terms of visual acuity gained at 2 months with a residual effect at
3 months and decreasing effect at 6 months.Limitations of this study are as follows: this was a non-
comparative study with a small sample size and relatively short
follow-up duration. The visual acuity was measured using the
Snellen visual acuity chart, which may not have the same consis-
tency as the Early Treatment of Diabetic Retinopathy Study chart.
Although we could conclude that the combination helps in early
and better visual recovery, a longer period of review will be needed
to document the sustainability of the treatment beneﬁt.
Although there will be continued debate over which combina-
tion is best, what will be the number of injections required for a
patient, and timing of the injections, our trial is among the ﬁrst to
investigate the combination of an anti-VEGF treatment and the
dexamethasone slow-release implant injected simultaneously. This
combined tailored treatment approach of bevacizumab and dexa-
methasone implant can be a new option to treat macular edema
due to vein occlusions where bevacizumab helps to achieve early
reduction of macular thickness on OCT, and dexamethasone
implant maintains the effect for a prolonged period, thereby
stretching out the interval between the injections, thus avoiding
frequent visits.References
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